TradingKey

Más Datos de Alkermes Plc Compañía

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Información de la empresa

Símbolo de cotizaciónALKS

Nombre de la empresaAlkermes Plc

Fecha de salida a bolsaJul 16, 1991

Director ejecutivoMr. Richard F. Pops

Número de empleados1800

Tipo de seguridadOrdinary Share

Fin del año fiscalJul 16

DirecciónConnaught House

CiudadDUBLIN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísIreland

Código postalD04 C5Y6

Teléfono35317728000

Sitio Webhttps://www.alkermes.com/

Símbolo de cotizaciónALKS

Fecha de salida a bolsaJul 16, 1991

Director ejecutivoMr. Richard F. Pops

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

204.25K

--

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

77.74K

--

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+26.46%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+12.23%

Ms. Nancy S. Lurker

Independent Director

10.71K

+131.91%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

204.25K

--

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

77.74K

--

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

VIVITROL

101.00M

32.95%

ARISTADA

73.47M

23.97%

LYBALVI

70.02M

22.84%

Royalty Revenue - VUMERITY

21.86M

7.13%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

17.75M

5.79%

Other

22.41M

7.31%

Sin datos

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

VIVITROL

101.00M

32.95%

ARISTADA

73.47M

23.97%

LYBALVI

70.02M

22.84%

Royalty Revenue - VUMERITY

21.86M

7.13%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

17.75M

5.79%

Other

22.41M

7.31%

Estadísticas de accionistas

Actualizado: sáb., 17 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

14.53%

The Vanguard Group, Inc.

11.00%

T. Rowe Price Associates, Inc.

7.04%

State Street Global Advisors (US)

4.86%

RTW Investments L.P.

4.17%

Other

58.40%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

14.53%

The Vanguard Group, Inc.

11.00%

T. Rowe Price Associates, Inc.

7.04%

State Street Global Advisors (US)

4.86%

RTW Investments L.P.

4.17%

Other

58.40%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

57.22%

Investment Advisor/Hedge Fund

30.61%

Hedge Fund

12.64%

Research Firm

2.77%

Individual Investor

1.66%

Pension Fund

1.62%

Sovereign Wealth Fund

1.24%

Bank and Trust

0.42%

Private Equity

0.36%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

769

179.19M

108.55%

-26.81M

2025Q1

781

180.42M

109.41%

-27.12M

2024Q4

750

175.04M

107.61%

-39.68M

2024Q3

727

186.93M

115.42%

-33.14M

2024Q2

708

187.79M

113.20%

-24.77M

2024Q1

682

184.21M

108.96%

-28.40M

2023Q4

653

184.12M

110.36%

-5.13M

2023Q3

620

171.53M

102.92%

-4.71M

2023Q2

610

167.10M

100.38%

-17.86M

2023Q1

604

167.47M

100.88%

-20.36M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

23.98M

14.54%

-541.92K

-2.21%

Mar 31, 2025

The Vanguard Group, Inc.

18.16M

11.01%

-283.51K

-1.54%

Mar 31, 2025

T. Rowe Price Associates, Inc.

11.62M

7.05%

-472.94K

-3.91%

Mar 31, 2025

State Street Global Advisors (US)

8.02M

4.87%

-792.30K

-8.99%

Mar 31, 2025

RTW Investments L.P.

6.88M

4.17%

-673.14K

-8.91%

Mar 31, 2025

Renaissance Technologies LLC

5.74M

3.48%

+260.10K

+4.75%

Mar 31, 2025

Baker Bros. Advisors LP

4.48M

2.72%

+301.53K

+7.21%

Mar 31, 2025

JP Morgan Asset Management

4.13M

2.5%

+3.88M

+1560.15%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.94M

2.39%

+121.05K

+3.17%

Mar 31, 2025

American Century Investment Management, Inc.

3.47M

2.1%

+14.97K

+0.43%

Mar 31, 2025

ETFs relacionados

Actualizado: sáb., 2 de ago

Nombre

Proporción

AdvisorShares Psychedelics ETF

6.14%

iShares Neuroscience and Healthcare ETF

3.95%

Invesco S&P SmallCap Health Care ETF

3.37%

First Trust NYSE Arca Biotechnology Index Fund

3.33%

ALPS Medical Breakthroughs ETF

3.19%

Tema Neuroscience and Mental Health ETF

1.88%

Knowledge Leaders Developed World ETF

1.68%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.4%

Invesco S&P SmallCap Quality ETF

1.34%

Janus Henderson Small Cap Growth Alpha ETF

1.25%

AdvisorShares Psychedelics ETF

Proporción6.14%

iShares Neuroscience and Healthcare ETF

Proporción3.95%

Invesco S&P SmallCap Health Care ETF

Proporción3.37%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.33%

ALPS Medical Breakthroughs ETF

Proporción3.19%

Tema Neuroscience and Mental Health ETF

Proporción1.88%

Knowledge Leaders Developed World ETF

Proporción1.68%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proporción1.4%

Invesco S&P SmallCap Quality ETF

Proporción1.34%

Janus Henderson Small Cap Growth Alpha ETF

Proporción1.25%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

Alkermes Plc

26.390USD

Alkermes Plc

26.390

Descripción general

Compañía

Finanzas